Buy Alert: Regeneron Stock Is Headed Higher
Regeneron Pharmaceuticals (NASDAQ: REGN) is one of the few companies selling a treatment for COVID-19. The U.S. Food and Drug Administration (FDA) authorized its antibody cocktail in November. Orders from the U.S. government represent more than $2.6 billion in sales so far. Regeneron sells other products, including blockbuster eye drug Eylea. And the company has more than 30 candidates in the pipeline.
But this hasn't helped share performance over the past year. The stock has slipped over that time period. The tide may be turning, however. Let's find out why shares of this innovative biotech company may be about to head higher.
Image source: Getty Images.
Source Fool.com
